BioRestorative Therapies, Inc.: insider trades · United States · SEC (Form 4)

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (ticker: BRTX) is a United States-based regenerative medicine company listed on NASDAQ. Headquartered in Melville, New York, the company develops stem cell-based therapies and related products, with an emphasis on adult stem cell science and translational medicine. From an equity-analyst perspective, BRTX should be viewed as a clinical-stage micro-cap biotech with meaningful binary risk, but also with upside optionality if its lead assets continue to advance through clinical and regulatory milestones. The company was founded by scientists and researchers focused on addressing unmet medical needs in highly prevalent conditions. Over time, it consolidated its operations in Melville, Long Island, where it maintains its headquarters and laboratory capabilities. BioRestorative’s business model is centered on two core programs. Its Disc/Spine program, branded brtxDISC, is led by BRTX-100, an autologous mesenchymal stem cell therapy derived from the patient’s own bone marrow and designed for chronic disc-related pain conditions. Its second platform, ThermoStem, targets metabolic disorders such as obesity through cell-based approaches involving brown adipose tissue biology and associated exosomes. In competitive terms, BioRestorative operates in a highly specialized and crowded regenerative medicine field where success depends on clinical differentiation, intellectual property strength, manufacturing know-how, and the ability to navigate FDA pathways. The addressable markets are large, particularly for chronic spinal pain and metabolic disease, but the company remains pre-commercial and therefore does not yet have the scale, revenue base, or de-risked profile of larger biotech peers. Investors are therefore largely underwriting scientific execution rather than current operating performance. Recent developments have been important. In 2025 and 2026, BioRestorative highlighted expanded Phase 2 data for BRTX-100, completion of enrollment in a randomized, double-blind, sham-controlled Phase 2 trial across 15 U.S. sites, and continued interaction with the FDA. The company also completed a $5 million public offering and has been managing capital carefully, which is typical for development-stage biotech. In April 2026, it announced a strategic collaboration with 203 Creates to build and commercialize a biocosmeceutical platform, showing an effort to broaden its commercial narrative beyond core clinical programs. For investors, BRTX combines early-stage regenerative medicine exposure with long-duration value creation potential, but also substantial clinical, financing, and execution risk.